Antidepressants to Carry Stronger Warnings on Suicidal Thoughts and Sexual Side Effects
Drug watchdogs are updating patient information leaflets and advising healthcare professionals to more prominently highlight risks associated with antidepressant use, including potential long-lasting sexual dysfunction.
Antidepressants will feature updated safety warnings regarding suicidal thoughts and persistent sexual side effects, according to new measures announced by health officials. Patient information leaflets are being revised to make these risks more apparent, incorporating boxed warnings and clearer directions to support services.
Patients will also be informed that certain antidepressants can lead to serious sexual problems that may continue even after treatment cessation. These symptoms can include genital numbness, loss of libido, erectile dysfunction, difficulties with orgasm, vaginal dryness, and low mood. The condition, known as Post SSRI Sexual Dysfunction (PSSD), has been a subject of debate, with some medical professionals questioning whether persistent sexual issues stem from the medication or underlying mental health conditions.
Regulators have now acknowledged, for the first time, that sexual dysfunction linked to antidepressants can endure after patients stop taking the drugs. This decision follows a comprehensive review by the Commission on Human Medicines, initiated in response to concerns from patients and their families about the communication of antidepressant risks.
Dr. Alison Cave, chief safety officer at the Medicines and Healthcare products Regulatory Agency (MHRA), stated, "Patients need clear and accessible information about the benefits and risks of medicines so they can make informed decisions." She added, "Antidepressants are effective medicines for the treatment of depression and other conditions. When used appropriately and under clinical supervision, for the vast majority of individuals, the benefits outweigh the risks. The aim is not to discourage use, but to improve the prominence and clarity of the existing warnings."
Healthcare professionals are also advised to discuss the risk of suicidal thoughts and behaviors with patients when initiating antidepressant treatment or adjusting dosages. The updated guidance comes amidst increasing attention on PSSD, with approximately one in seven adults currently taking antidepressants.
While mental health conditions like depression and anxiety can naturally reduce libido, and antidepressants can also affect sexual function, these issues typically improve for most patients after discontinuing the medication or reducing the dose. PSSD specifically refers to cases where sexual symptoms persist for months or years after SSRI use has ended, with some patients reporting what they believe to be permanent symptoms.
The MHRA has strengthened its warnings concerning suicidal thoughts and sexual dysfunction, noting evidence that certain antidepressants, including duloxetine, fluvoxamine, and fluoxetine, are associated with a risk of sexual dysfunction that may persist post-treatment. These drugs function by blocking the reabsorption of serotonin in the brain to help regulate mood and emotion.
Patients currently taking antidepressants will receive the updated leaflets in 2027. Individuals on these medications are strongly advised not to discontinue treatment without consulting a healthcare professional.